UPDATE : Friday, June 5, 2020
HOME Pharma
AptaBio attending J.P. Morgan event for global collaboration
  • By Shim Hyun-tai
  • Published 2020.01.15 13:06
  • Updated 2020.01.15 22:34
  • comments 0

AptaBio, a maker of drugs to treat cancer and diabetic complications, said it is participating in the 2020 J.P. Morgan Healthcare Conference to strengthen global competence and seek business collaborations.

Multinational pharmaceutical companies share their research and development results from Monday to Friday at the conference, the world's largest biotech meet to track the global market trend, which is being held in San Francisco, California. About 9,000 people from 480 private and public enterprises are likely to attend the event.

AptaBio said it plans to have extensive one-on-one talks with global pharmaceutical and biotechnology companies during the conference.

In these meetings, the company will explain its core technologies, NOX (nicotinamide adenine dinucleotide phosphate oxidase) inhibitor discovery and Apta-DC platform. It also will sound out possibilities for detailed collaboration and license-out (LO) deals based on the ongoing clinical development of diabetic complication drugs and anti-cancer immune disease pipeline.

"J.P. Morgan Healthcare Conference is a venue for information exchange in the biotechnology field. However, it is also for direct technology exports, so AptaBio is working on expanding collaboration opportunities," an AptaBio official said.

Those separate meetings were meaningful since the company’s base technology of diabetic complication drugs attracted considerable attention, and diabetic nephropathy drug, APX-115, was entering phase 2 clinical trial, the official added.

AptaBio aims to make five license-out deals by the end of this year, including the three previously made ones, the company said in a news release. It also has been conducting discussions with top global pharmaceutical and biotechnology companies.

“Aptabio has been actively taking part in global conferences such as Europe's largest biotechnology and pharmaceutical forum, “BIO-Europe 2019,” and J.P. Morgan Healthcare Conference to promote our business,” according to the press release.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Shim Hyun-tai
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top